logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
L

Lin Yu

fudan university shanghai cancer center
H指数:23
被引数:1,522

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Di-2-ethylhexyl Phthalate Reprograms Epithelial-Mesenchymal Transition and Lenvatinib Responsiveness in Hepatoma Cells via SPAG4-Dependent MAPK/ERK Signaling

邻苯二甲酸二（2-乙基己基）酯通过SPAG4依赖的MAPK/ERK信号通路重编程肝细胞癌上皮-间质转化和对仑伐替尼的响应

Chemical Research in Toxicology
IF3.8
2026-05-010
PRE
Yang, QiWei; Yu, Lin; Tang, Ran; Peng, YiShan; Huang, Tao; Chen, HaoQi; Zhu, WenFeng; Yuan, Qing; Wang, Wei; Jiang, Xiaojian; Ma, ZhiLi; Yuan, Lei; Wang, SuMei; Wang, XiaoWen; Wang, GenShu
ESO-Shanghai 20: phase III clinical trial of anti-PD-1 therapy with local intervention for oligometastatic ESCC

ESO-上海20：局部干预联合抗PD-1疗法治疗寡转移性ESCC的III期临床试验

Future Oncology
IF2.6
2025-07-300
OA
Guangmin Mao; Zhuocheng Xin; Qingsong Fan; Huijuan Zhu; Jinjun Ye; Long Zhou; Yufeng He; Benhua Xu; Cheng Chen; Zhijun Li; Xiaowei Gu; Xianfeng Li; Xiaomin Wang; Junjun Guo; Zhengyang Xu; Peng Wan; Yunxia Zhang; Fuzheng Zhang; Canhong Huang; Qiong Yi; Jiangqiong Huang; Shixiong Liang; Junqiang Chen; Yu Lin; Qingliang Fang; Yun Chen; Dashan Ai; Hongcheng Zhu; Shengnan Hao; Qi Liu; Kuaile Zhao
Effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients with advanced/recurrent or metastatic esophageal squamous cell carcinoma in China: a real-world multicenter study

中国晚期/复发或转移性食管鳞状细胞癌患者一线派姆单抗联合化疗的有效性和安全性: 一项真实世界的多中心研究

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2024-11-190
OAAI
Lin, Yu; Shen, Wenbin; Ye, Jinjun; Luo, Honglei; Zhang, Xizhi; Xu, Yuanji; Lin, Qin; Liu, Wenyang; Zhang, Yingying; Xu, Yujin; Jiang, Wei; Zhao, Lina; Liu, Anwen; Wu, Lei; Ge, Hong; Xie, Conghua; Zhao, Kuaile; Chen, Junqiang; Wang, Luhua; Liu, Qi

研究方向

暂未获取到该数据
I
I Weng Lao
H 指数:16论文数:46被引数:884
J
Jian Wang
H 指数:21论文数:94被引数:1,184
W
Wentao Yang
H 指数:48论文数:302被引数:7,257
Q
Qianming Bai
H 指数:24论文数:126被引数:1,707
R
Rui Bi
H 指数:45论文数:295被引数:5,459
X
Xiu Qin Xu
H 指数:16论文数:44被引数:1,182
X
Xiaoyan Zhou
H 指数:29论文数:134被引数:2,814
X
Xu Kong
H 指数:7论文数:21被引数:258
W
Wangjun Yan
H 指数:24论文数:140被引数:1,985
X
Xiaoyan Zhou
H 指数:37论文数:200被引数:6,295